• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by KemPharm Inc. (Amendment)

    5/17/21 4:43:32 PM ET
    $KMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KMPH alert in real time by email
    SC 13G/A 1 braun_sc13ga1.htm AMENDMENT NO. 1

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Amendment No. 1) 

     

    Under the Securities Exchange Act of 1934

     

    KemPharm, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    488445 206

    (CUSIP Number)

     

    May 10, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐  Rule 13d-1(b)
    ☒  Rule 13d-1(c)
    ☐  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

       

     

     

             
    CUSIP No. 488445 206   13G/A   Page 2 of 6 Pages
             

     

             
    1.   NAMES OF REPORTING PERSONS
    Samuel J. Braun
       
    2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    
    ¨
    (b)    
    ¨
       
    3.   SEC USE ONLY
     
       
    4.   CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
       

     

             
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH   5.   SOLE VOTING POWER
     
    3,155,000
      6.   SHARED VOTING POWER
     
    0
      7.   SOLE DISPOSITIVE POWER
     
    3,155,000
      8.   SHARED DISPOSITIVE POWER
     
    0

     

             
    9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,155,000
       
    10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    
    ¨
       
    11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    11.1% (1)
       
    12.   TYPE OF REPORTING PERSON

    IN
       
             

     

    (1) Based on 28,507,297 shares of common stock outstanding as of May 12, 2021, as represented in the quarterly report on Form 10-Q filed by KemPharm, Inc. with the Securities and Exchange Commission on May 14, 2021.

     

       

     

     

    CUSIP No. 488445 206   13G/A   Page 3 of 6 Pages

     

     

    Item 1(a)Name of Issuer:

     

    KemPharm, Inc.

     

    Item 1(b)Address of Issuer's Principal Executive Offices:

     

    1180 Celebration Boulevard, Suite 103

    Celebration, Florida 34747

     

    Item 2(a)Name of Person Filing:

     

    Samuel J. Braun

     

    Item 2(b)Address of Principal Business Office or, if none, Residence:

     

    5 West Main St.

    Box 361

    Warner, South Dakota 57479-0361

     

    Item 2(c)Citizenship:

     

    USA

     

    Item 2(d)Title of Class of Securities:

     

    Common Stock, par value $0.0001 (“Common Stock”)

     

    Item 2(e)CUSIP Number:

     

    488445 206

     

    Item 3.If this statement is filed pursuant to § § 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a(n):

     

     

      (a) [  ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) [  ]   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) [  ]   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) [  ] Investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) [  ] Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) [  ]   Parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) [  ] Savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) [  ]   Church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j) [  ]   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) [  ]   Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

     

     

     

       

     

     

    CUSIP No. 488445 206   13G/A   Page 4 of 6 Pages

     

    Item 4.  Ownership.

     

      (a) Amount beneficially owned:

     

    3,155,000 shares of Common Stock

      

    3,012,000 shares of Common Stock reported are held by the reporting person individually, consisting of 3,010,000 issued and outstanding shares and call options to purchase up to 2,000 shares on August 20, 2021. 10,000 of these shares were purchased after the date triggering this amendment but prior to filing hereof.

     

    60,000 shares of Common Stock reported are held by the reporting person and his sibling in an account with common ownership, but over which the reporting person exercises sole voting and dispositive power.

     

    68,000 shares of Common Stock reported are held by Thinkswitch Capitol, LLC, a related entity, over which shares of Common Stock the reporting person has the sole voting and dispositive power.

     

    15,000 shares of Common Stock reported are held by ThetaBurn Investments, LLC, a related entity, over which shares of Common Stock the reporting person has the sole voting and dispositive power.

     

      (b) Percent of class:
        11.1%

     

      (c) Number of shares as to which the person has: 

     

      (i) sole power to vote or to direct the vote:
        3,155,000
         
      (ii) shared power to vote or to direct the vote
        0
      (iii) sole power to dispose or to direct the disposition of:
        3,155,000
         
      (iv) shared power to dispose or to direct the disposition of:
        0

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. [   ]

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    The other members of each of the related entities over which the reporting person exercises sole voting and dispositive power have the right to participate in the receipt of dividends from, and proceeds from the sale of, the shares in accordance with their respective ownership interests in such entities. The reporting person’s sibling has the right to participated in the receipt of dividends from, and proceeds from the sale of, the shares held in the common brokerage account managed solely by the reporting person. 

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

     

     

       

     

     

    CUSIP No. 488445 206   13G/A   Page 5 of 6 Pages

     

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     

    [Signature Page Follows]

     

     

     

     

     

     

     

     

       

     

     

    CUSIP No. 488445 206   13G/A   Page 6 of 6 Pages

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Dated: May 17, 2021

     

    /s/ Samuel J. Braun

    Samuel J. Braun

    Get the next $KMPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KMPH

    DatePrice TargetRatingAnalyst
    11/17/2022$20.00Overweight
    Cantor Fitzgerald
    9/15/2022$20.00Buy
    Canaccord Genuity
    1/31/2022$10.00 → $11.00Neutral → Buy
    HC Wainwright & Co.
    More analyst ratings

    $KMPH
    Leadership Updates

    Live Leadership Updates

    See more
    • KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company

      Matthew R. Plooster named Chairman of the Board of DirectorsRichard W. Pascoe appointed Chief Executive OfficerTravis C. Mickle, Ph.D. transitions to PresidentJoshua Schafer appointed Chief Commercial Officer and Executive Vice President of Business Development CELEBRATION, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS), neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced changes to its Board of Directors (Board) and executive leadership team as part of the Company's ongoing b

      1/9/23 6:30:00 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Announces Appointment of Christopher Posner as New Independent Director

      24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm's Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS) and neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the appointment of Christopher Posner to serve on the Company's Board of Directors. Mr. Posner is currently the president and CEO of Cara Therapeutics (NASDAQ:CARA), a commercial-stage biopharmaceutical company.

      11/29/22 7:30:00 AM ET
      $CARA
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications

      CELEBRATION, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced the appointment of Nichol Ochsner to the role of Vice President, Investor Relations and Corporate Communications. In this newly created position, Ms. Ochsner will be responsible for driving external awareness of KemPharm's value proposition, including ongoing relations with the Company's shareholders, covering analysts and prospective investors. "We are very plea

      8/9/22 7:30:00 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMPH
    Financials

    Live finance-specific insights

    See more
    • Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

      CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022. The audio webcast with a slide presentation will be accessible via the Investor Relations section of the Company's website, http://investors.zevra.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately 9:30 a.m. ET, on March 7, 2023. Additionally, in

      2/27/23 7:30:00 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Reports Third Quarter 2022 Results

      Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 9, 2022, at 5:00 p.m. ET Significant activities underway for preparation of the arimoclomol NDA resubmissionAdvancing key activities to initiate a Phase 2 clinical trial of KP1077 in IH by year-end 2022Total cash (cash, cash equivalents and long-term investments) of $107.4M as of Sep 30, 2022; based on current operating forecast, cash runway extends into 2026 CELEBRATION, Fla., Nov. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare central ne

      11/9/22 4:05:00 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm to Report Third Quarter 2022 Financial Results

      CELEBRATION, Fla., Nov. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization of novel treatments for rare diseases, today announced that the Company will host a conference call and live audio webcast on Wednesday, November 9, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the third quarter 2022. The audio webcast with slide presentation will be accessible via the Investor Relations section of the Company's website, http://investors.kempharm.com/. An archive of the webcast and presentation will be available for 90 days beginning at approximately 6:

      11/1/22 7:30:00 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on KemPharm with a new price target

      Cantor Fitzgerald initiated coverage of KemPharm with a rating of Overweight and set a new price target of $20.00

      11/17/22 7:28:54 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on KemPharm with a new price target

      Canaccord Genuity initiated coverage of KemPharm with a rating of Buy and set a new price target of $20.00

      9/15/22 7:21:45 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded KemPharm from Neutral to Buy and set a new price target of $11.00 from $10.00 previously

      1/31/22 7:18:55 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zevra Therapeutics Begins Trading as ZVRA

      Company's common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol "ZVRA" starting today, March 1, 2023 New Company name, Zevra, is Greek for zebra, the internationally recognized symbol for the rare disease community CELEBRATION, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NASDAQ:ZVRA) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol "ZVRA" on the Nasdaq Global Select Market at market open today, March 1, 2023. The Company's new corporate name, along with the corresponding ticker symbol, embody Zevra's unwa

      3/1/23 7:43:50 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)

      CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) ("Zevra" or the "Company" and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Organization for Rare Disorders (NORD) and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023. A rare disease is a condition that impacts fewer than 200,000 people in the United States, with over 7,000 known rare diseases nationally affecting nearly 1 in 10 people. NORD is dedicated to promoting research and access to therapies for the more than 300 million people worldwide with rare disea

      2/28/23 8:00:00 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

      CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) ("Zevra" or the "Company" and formerly known as KemPharm, Inc.), today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with the Company's 2023 Annual Meeting of Stockholders ("Annual Meeting"), which is scheduled to take place on April 25, 2023. Stockholders do not need to take any action with respect to the 2023 Annual Meeting at this time. In its preliminary proxy statement, Zevra announced that the Board has nominated three directors for re-election at the Company's Annual Meeting — Richard W. Pascoe, David S. Tier

      2/27/23 4:30:03 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMPH
    SEC Filings

    See more
    • SEC Form S-3 filed by KemPharm Inc.

      S-3 - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      2/2/24 9:39:30 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Inc. filed SEC Form 8-K: Leadership Update

      8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      1/23/24 7:37:15 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KemPharm Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

      1/8/24 8:03:19 AM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by KemPharm Inc.

      SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

      2/14/24 4:51:40 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by KemPharm Inc.

      SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

      1/29/24 5:25:49 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by KemPharm Inc.

      SC 13G - KEMPHARM, INC (0001434647) (Subject)

      7/8/22 4:57:01 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Schafer Joshua

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      2/2/24 9:22:49 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sangiovanni Timothy J.

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      2/2/24 8:17:46 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Mickle Christal M M

      4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

      2/2/24 8:14:52 PM ET
      $KMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care